Loading…

The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity

Systemic light chain (AL) amyloidosis is caused by the clonal production of an unstable immunoglobulin light chain (LC), which affects organ function systemically. Although pathogenic LCs have been characterized biochemically, little is known about the biology of amyloidogenic plasma cells (PCs). In...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2017-04, Vol.129 (15), p.2132-2142
Main Authors: Oliva, Laura, Orfanelli, Ugo, Resnati, Massimo, Raimondi, Andrea, Orsi, Andrea, Milan, Enrico, Palladini, Giovanni, Milani, Paolo, Cerruti, Fulvia, Cascio, Paolo, Casarini, Simona, Rognoni, Paola, Touvier, Thierry, Marcatti, Magda, Ciceri, Fabio, Mangiacavalli, Silvia, Corso, Alessandro, Merlini, Giampaolo, Cenci, Simone
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c408t-6987e36e237a2f2bd6c77c0ccbf7534b215027115affce61ad029b78964c0ec13
cites cdi_FETCH-LOGICAL-c408t-6987e36e237a2f2bd6c77c0ccbf7534b215027115affce61ad029b78964c0ec13
container_end_page 2142
container_issue 15
container_start_page 2132
container_title Blood
container_volume 129
creator Oliva, Laura
Orfanelli, Ugo
Resnati, Massimo
Raimondi, Andrea
Orsi, Andrea
Milan, Enrico
Palladini, Giovanni
Milani, Paolo
Cerruti, Fulvia
Cascio, Paolo
Casarini, Simona
Rognoni, Paola
Touvier, Thierry
Marcatti, Magda
Ciceri, Fabio
Mangiacavalli, Silvia
Corso, Alessandro
Merlini, Giampaolo
Cenci, Simone
description Systemic light chain (AL) amyloidosis is caused by the clonal production of an unstable immunoglobulin light chain (LC), which affects organ function systemically. Although pathogenic LCs have been characterized biochemically, little is known about the biology of amyloidogenic plasma cells (PCs). Intrigued by the unique response rates of AL amyloidosis patients to the first-in-class proteasome inhibitor (PI) bortezomib, we purified and investigated patient-derived AL PCs, in comparison with primary multiple myeloma (MM) PCs, the prototypical PI-responsive cells. Functional, biochemical, and morphological characterization revealed an unprecedented intrinsic sensitivity of AL PCs to PIs, even higher than that of MM PCs, associated with distinctive organellar features and expression patterns indicative of cellular stress. These consisted of expanded endoplasmic reticulum (ER), perinuclear mitochondria, and a higher abundance of stress-related transcripts, and were consistent with reduced autophagic control of organelle homeostasis. To test whether PI sensitivity stems from AL LC production, we engineered PC lines that can be induced to express amyloidogenic and nonamyloidogenic LCs, and found that AL LC expression alters cell growth and proteostasis and confers PI sensitivity. Our study discloses amyloidogenic LC production as an intrinsic PC stressor, and identifies stress-responsive pathways as novel potential therapeutic targets. Moreover, we contribute a cellular disease model to dissect the biology of AL PCs. •Amyloidogenic PCs show unique PI susceptibility and altered organelle homeostasis, consistent with defective autophagy.•Amyloidogenic LC production is an intrinsic cellular stressor that sensitizes to PI toxicity.
doi_str_mv 10.1182/blood-2016-08-730978
format article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2016_08_730978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000649712033490X</els_id><sourcerecordid>S000649712033490X</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-6987e36e237a2f2bd6c77c0ccbf7534b215027115affce61ad029b78964c0ec13</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EouXxBwj5BwJj52Fng4QqXhISm7K2HGdCBiVxZRtE-XpaCixZ3c09M1eHsTMBF0JoedkM3reZBFFloDOVQ630HpuLUuoMQMI-mwNAlRW1EjN2FOMrgChyWR6ymdQiBymKOaNlj9yO68FT619wIscHeukTd72liVPklscUMEYfeOpt4hGnSIk-MfLVYONoucNhiDx5vgo-oY1-RE5TTw2lLeQ_yFFan7CDzg4RT3_ymD3f3iwX99nj093D4voxcwXolFW1VphXKHNlZSebtnJKOXCu6VSZF40UJUglRGm7zmElbAuybpSuq8IBOpEfs2J31wUfY8DOrAKNNqyNALM1Z77Nma05A9rszG2w8x22emtGbP-gX1WbwtWugJvx74TBREc4OWwpoEum9fT_hy-7toIc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity</title><source>ScienceDirect Journals</source><creator>Oliva, Laura ; Orfanelli, Ugo ; Resnati, Massimo ; Raimondi, Andrea ; Orsi, Andrea ; Milan, Enrico ; Palladini, Giovanni ; Milani, Paolo ; Cerruti, Fulvia ; Cascio, Paolo ; Casarini, Simona ; Rognoni, Paola ; Touvier, Thierry ; Marcatti, Magda ; Ciceri, Fabio ; Mangiacavalli, Silvia ; Corso, Alessandro ; Merlini, Giampaolo ; Cenci, Simone</creator><creatorcontrib>Oliva, Laura ; Orfanelli, Ugo ; Resnati, Massimo ; Raimondi, Andrea ; Orsi, Andrea ; Milan, Enrico ; Palladini, Giovanni ; Milani, Paolo ; Cerruti, Fulvia ; Cascio, Paolo ; Casarini, Simona ; Rognoni, Paola ; Touvier, Thierry ; Marcatti, Magda ; Ciceri, Fabio ; Mangiacavalli, Silvia ; Corso, Alessandro ; Merlini, Giampaolo ; Cenci, Simone</creatorcontrib><description>Systemic light chain (AL) amyloidosis is caused by the clonal production of an unstable immunoglobulin light chain (LC), which affects organ function systemically. Although pathogenic LCs have been characterized biochemically, little is known about the biology of amyloidogenic plasma cells (PCs). Intrigued by the unique response rates of AL amyloidosis patients to the first-in-class proteasome inhibitor (PI) bortezomib, we purified and investigated patient-derived AL PCs, in comparison with primary multiple myeloma (MM) PCs, the prototypical PI-responsive cells. Functional, biochemical, and morphological characterization revealed an unprecedented intrinsic sensitivity of AL PCs to PIs, even higher than that of MM PCs, associated with distinctive organellar features and expression patterns indicative of cellular stress. These consisted of expanded endoplasmic reticulum (ER), perinuclear mitochondria, and a higher abundance of stress-related transcripts, and were consistent with reduced autophagic control of organelle homeostasis. To test whether PI sensitivity stems from AL LC production, we engineered PC lines that can be induced to express amyloidogenic and nonamyloidogenic LCs, and found that AL LC expression alters cell growth and proteostasis and confers PI sensitivity. Our study discloses amyloidogenic LC production as an intrinsic PC stressor, and identifies stress-responsive pathways as novel potential therapeutic targets. Moreover, we contribute a cellular disease model to dissect the biology of AL PCs. •Amyloidogenic PCs show unique PI susceptibility and altered organelle homeostasis, consistent with defective autophagy.•Amyloidogenic LC production is an intrinsic cellular stressor that sensitizes to PI toxicity.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2016-08-730978</identifier><identifier>PMID: 28130214</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Amyloidosis - drug therapy ; Amyloidosis - metabolism ; Amyloidosis - pathology ; Bortezomib - pharmacokinetics ; Endoplasmic Reticulum - metabolism ; Endoplasmic Reticulum - pathology ; Female ; Humans ; Immunoglobulin Light Chains - biosynthesis ; Male ; Mitochondria - metabolism ; Mitochondria - pathology ; Multiple Myeloma - drug therapy ; Multiple Myeloma - metabolism ; Multiple Myeloma - pathology ; Plasma Cells - metabolism ; Plasma Cells - pathology ; Proteasome Inhibitors - pharmacokinetics</subject><ispartof>Blood, 2017-04, Vol.129 (15), p.2132-2142</ispartof><rights>2017 American Society of Hematology</rights><rights>2017 by The American Society of Hematology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-6987e36e237a2f2bd6c77c0ccbf7534b215027115affce61ad029b78964c0ec13</citedby><cites>FETCH-LOGICAL-c408t-6987e36e237a2f2bd6c77c0ccbf7534b215027115affce61ad029b78964c0ec13</cites><orcidid>0000-0003-1215-7518</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S000649712033490X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28130214$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oliva, Laura</creatorcontrib><creatorcontrib>Orfanelli, Ugo</creatorcontrib><creatorcontrib>Resnati, Massimo</creatorcontrib><creatorcontrib>Raimondi, Andrea</creatorcontrib><creatorcontrib>Orsi, Andrea</creatorcontrib><creatorcontrib>Milan, Enrico</creatorcontrib><creatorcontrib>Palladini, Giovanni</creatorcontrib><creatorcontrib>Milani, Paolo</creatorcontrib><creatorcontrib>Cerruti, Fulvia</creatorcontrib><creatorcontrib>Cascio, Paolo</creatorcontrib><creatorcontrib>Casarini, Simona</creatorcontrib><creatorcontrib>Rognoni, Paola</creatorcontrib><creatorcontrib>Touvier, Thierry</creatorcontrib><creatorcontrib>Marcatti, Magda</creatorcontrib><creatorcontrib>Ciceri, Fabio</creatorcontrib><creatorcontrib>Mangiacavalli, Silvia</creatorcontrib><creatorcontrib>Corso, Alessandro</creatorcontrib><creatorcontrib>Merlini, Giampaolo</creatorcontrib><creatorcontrib>Cenci, Simone</creatorcontrib><title>The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity</title><title>Blood</title><addtitle>Blood</addtitle><description>Systemic light chain (AL) amyloidosis is caused by the clonal production of an unstable immunoglobulin light chain (LC), which affects organ function systemically. Although pathogenic LCs have been characterized biochemically, little is known about the biology of amyloidogenic plasma cells (PCs). Intrigued by the unique response rates of AL amyloidosis patients to the first-in-class proteasome inhibitor (PI) bortezomib, we purified and investigated patient-derived AL PCs, in comparison with primary multiple myeloma (MM) PCs, the prototypical PI-responsive cells. Functional, biochemical, and morphological characterization revealed an unprecedented intrinsic sensitivity of AL PCs to PIs, even higher than that of MM PCs, associated with distinctive organellar features and expression patterns indicative of cellular stress. These consisted of expanded endoplasmic reticulum (ER), perinuclear mitochondria, and a higher abundance of stress-related transcripts, and were consistent with reduced autophagic control of organelle homeostasis. To test whether PI sensitivity stems from AL LC production, we engineered PC lines that can be induced to express amyloidogenic and nonamyloidogenic LCs, and found that AL LC expression alters cell growth and proteostasis and confers PI sensitivity. Our study discloses amyloidogenic LC production as an intrinsic PC stressor, and identifies stress-responsive pathways as novel potential therapeutic targets. Moreover, we contribute a cellular disease model to dissect the biology of AL PCs. •Amyloidogenic PCs show unique PI susceptibility and altered organelle homeostasis, consistent with defective autophagy.•Amyloidogenic LC production is an intrinsic cellular stressor that sensitizes to PI toxicity.</description><subject>Amyloidosis - drug therapy</subject><subject>Amyloidosis - metabolism</subject><subject>Amyloidosis - pathology</subject><subject>Bortezomib - pharmacokinetics</subject><subject>Endoplasmic Reticulum - metabolism</subject><subject>Endoplasmic Reticulum - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin Light Chains - biosynthesis</subject><subject>Male</subject><subject>Mitochondria - metabolism</subject><subject>Mitochondria - pathology</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - metabolism</subject><subject>Multiple Myeloma - pathology</subject><subject>Plasma Cells - metabolism</subject><subject>Plasma Cells - pathology</subject><subject>Proteasome Inhibitors - pharmacokinetics</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EouXxBwj5BwJj52Fng4QqXhISm7K2HGdCBiVxZRtE-XpaCixZ3c09M1eHsTMBF0JoedkM3reZBFFloDOVQ630HpuLUuoMQMI-mwNAlRW1EjN2FOMrgChyWR6ymdQiBymKOaNlj9yO68FT619wIscHeukTd72liVPklscUMEYfeOpt4hGnSIk-MfLVYONoucNhiDx5vgo-oY1-RE5TTw2lLeQ_yFFan7CDzg4RT3_ymD3f3iwX99nj093D4voxcwXolFW1VphXKHNlZSebtnJKOXCu6VSZF40UJUglRGm7zmElbAuybpSuq8IBOpEfs2J31wUfY8DOrAKNNqyNALM1Z77Nma05A9rszG2w8x22emtGbP-gX1WbwtWugJvx74TBREc4OWwpoEum9fT_hy-7toIc</recordid><startdate>20170413</startdate><enddate>20170413</enddate><creator>Oliva, Laura</creator><creator>Orfanelli, Ugo</creator><creator>Resnati, Massimo</creator><creator>Raimondi, Andrea</creator><creator>Orsi, Andrea</creator><creator>Milan, Enrico</creator><creator>Palladini, Giovanni</creator><creator>Milani, Paolo</creator><creator>Cerruti, Fulvia</creator><creator>Cascio, Paolo</creator><creator>Casarini, Simona</creator><creator>Rognoni, Paola</creator><creator>Touvier, Thierry</creator><creator>Marcatti, Magda</creator><creator>Ciceri, Fabio</creator><creator>Mangiacavalli, Silvia</creator><creator>Corso, Alessandro</creator><creator>Merlini, Giampaolo</creator><creator>Cenci, Simone</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-1215-7518</orcidid></search><sort><creationdate>20170413</creationdate><title>The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity</title><author>Oliva, Laura ; Orfanelli, Ugo ; Resnati, Massimo ; Raimondi, Andrea ; Orsi, Andrea ; Milan, Enrico ; Palladini, Giovanni ; Milani, Paolo ; Cerruti, Fulvia ; Cascio, Paolo ; Casarini, Simona ; Rognoni, Paola ; Touvier, Thierry ; Marcatti, Magda ; Ciceri, Fabio ; Mangiacavalli, Silvia ; Corso, Alessandro ; Merlini, Giampaolo ; Cenci, Simone</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-6987e36e237a2f2bd6c77c0ccbf7534b215027115affce61ad029b78964c0ec13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Amyloidosis - drug therapy</topic><topic>Amyloidosis - metabolism</topic><topic>Amyloidosis - pathology</topic><topic>Bortezomib - pharmacokinetics</topic><topic>Endoplasmic Reticulum - metabolism</topic><topic>Endoplasmic Reticulum - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin Light Chains - biosynthesis</topic><topic>Male</topic><topic>Mitochondria - metabolism</topic><topic>Mitochondria - pathology</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - metabolism</topic><topic>Multiple Myeloma - pathology</topic><topic>Plasma Cells - metabolism</topic><topic>Plasma Cells - pathology</topic><topic>Proteasome Inhibitors - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oliva, Laura</creatorcontrib><creatorcontrib>Orfanelli, Ugo</creatorcontrib><creatorcontrib>Resnati, Massimo</creatorcontrib><creatorcontrib>Raimondi, Andrea</creatorcontrib><creatorcontrib>Orsi, Andrea</creatorcontrib><creatorcontrib>Milan, Enrico</creatorcontrib><creatorcontrib>Palladini, Giovanni</creatorcontrib><creatorcontrib>Milani, Paolo</creatorcontrib><creatorcontrib>Cerruti, Fulvia</creatorcontrib><creatorcontrib>Cascio, Paolo</creatorcontrib><creatorcontrib>Casarini, Simona</creatorcontrib><creatorcontrib>Rognoni, Paola</creatorcontrib><creatorcontrib>Touvier, Thierry</creatorcontrib><creatorcontrib>Marcatti, Magda</creatorcontrib><creatorcontrib>Ciceri, Fabio</creatorcontrib><creatorcontrib>Mangiacavalli, Silvia</creatorcontrib><creatorcontrib>Corso, Alessandro</creatorcontrib><creatorcontrib>Merlini, Giampaolo</creatorcontrib><creatorcontrib>Cenci, Simone</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oliva, Laura</au><au>Orfanelli, Ugo</au><au>Resnati, Massimo</au><au>Raimondi, Andrea</au><au>Orsi, Andrea</au><au>Milan, Enrico</au><au>Palladini, Giovanni</au><au>Milani, Paolo</au><au>Cerruti, Fulvia</au><au>Cascio, Paolo</au><au>Casarini, Simona</au><au>Rognoni, Paola</au><au>Touvier, Thierry</au><au>Marcatti, Magda</au><au>Ciceri, Fabio</au><au>Mangiacavalli, Silvia</au><au>Corso, Alessandro</au><au>Merlini, Giampaolo</au><au>Cenci, Simone</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2017-04-13</date><risdate>2017</risdate><volume>129</volume><issue>15</issue><spage>2132</spage><epage>2142</epage><pages>2132-2142</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Systemic light chain (AL) amyloidosis is caused by the clonal production of an unstable immunoglobulin light chain (LC), which affects organ function systemically. Although pathogenic LCs have been characterized biochemically, little is known about the biology of amyloidogenic plasma cells (PCs). Intrigued by the unique response rates of AL amyloidosis patients to the first-in-class proteasome inhibitor (PI) bortezomib, we purified and investigated patient-derived AL PCs, in comparison with primary multiple myeloma (MM) PCs, the prototypical PI-responsive cells. Functional, biochemical, and morphological characterization revealed an unprecedented intrinsic sensitivity of AL PCs to PIs, even higher than that of MM PCs, associated with distinctive organellar features and expression patterns indicative of cellular stress. These consisted of expanded endoplasmic reticulum (ER), perinuclear mitochondria, and a higher abundance of stress-related transcripts, and were consistent with reduced autophagic control of organelle homeostasis. To test whether PI sensitivity stems from AL LC production, we engineered PC lines that can be induced to express amyloidogenic and nonamyloidogenic LCs, and found that AL LC expression alters cell growth and proteostasis and confers PI sensitivity. Our study discloses amyloidogenic LC production as an intrinsic PC stressor, and identifies stress-responsive pathways as novel potential therapeutic targets. Moreover, we contribute a cellular disease model to dissect the biology of AL PCs. •Amyloidogenic PCs show unique PI susceptibility and altered organelle homeostasis, consistent with defective autophagy.•Amyloidogenic LC production is an intrinsic cellular stressor that sensitizes to PI toxicity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28130214</pmid><doi>10.1182/blood-2016-08-730978</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-1215-7518</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2017-04, Vol.129 (15), p.2132-2142
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2016_08_730978
source ScienceDirect Journals
subjects Amyloidosis - drug therapy
Amyloidosis - metabolism
Amyloidosis - pathology
Bortezomib - pharmacokinetics
Endoplasmic Reticulum - metabolism
Endoplasmic Reticulum - pathology
Female
Humans
Immunoglobulin Light Chains - biosynthesis
Male
Mitochondria - metabolism
Mitochondria - pathology
Multiple Myeloma - drug therapy
Multiple Myeloma - metabolism
Multiple Myeloma - pathology
Plasma Cells - metabolism
Plasma Cells - pathology
Proteasome Inhibitors - pharmacokinetics
title The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A58%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20amyloidogenic%20light%20chain%20is%20a%20stressor%20that%20sensitizes%20plasma%20cells%20to%20proteasome%20inhibitor%20toxicity&rft.jtitle=Blood&rft.au=Oliva,%20Laura&rft.date=2017-04-13&rft.volume=129&rft.issue=15&rft.spage=2132&rft.epage=2142&rft.pages=2132-2142&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2016-08-730978&rft_dat=%3Celsevier_cross%3ES000649712033490X%3C/elsevier_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c408t-6987e36e237a2f2bd6c77c0ccbf7534b215027115affce61ad029b78964c0ec13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/28130214&rfr_iscdi=true